Cabozantinib in Combination With 13-cis-Retinoic Acid in Children With Relapsed or Refractory Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT03611595

Recruitment Status : Recruiting

First Posted : August 2, 2018

Last Update Posted : October 8, 2021

See Contacts and Locations

Sponsor:

Collaborator:

Exelixis

Information provided by (Responsible Party):

Peter Zage, University of California, San Diego

Study Details
Tabular View
No Results Posted
Disclaimer
How to Read a Study Record

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Recruiting
Estimated Primary Completion Date :	August 2022
Estimated Study Completion Date :	December 2022

To Top